Breaking News Instant updates and real-time market news.

REGN

Regeneron

$355.44

2.81 (0.80%)

06:38
11/06/18
11/06
06:38
11/06/18
06:38

Regeneron reports Q3 Eylea global net sales up 11% to $1.68B

Net product sales were $1.025 billion in the third quarter of 2018, compared to $957 million in the third quarter of 2017. Eylea net product sales in the United States were $1.022 billion in the third quarter of 2018, compared to $953 million in the third quarter of 2017. Overall distributor inventory levels for Eylea in the United States remained within the company's one-to-two-week targeted range.

  • 06

    Nov

  • 27

    Nov

  • 28

    Apr

  • 13

    May

REGN Regeneron
$355.44

2.81 (0.80%)

10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:30
02/19/19
02/19
07:30
02/19/19
07:30
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$80.53

-1.47 (-1.79%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Recommendations
Choice Hotels analyst commentary  »

Choice Hotels reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$5.64

-0.07 (-1.23%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Hot Stocks
Aptinyx doses first patient in Phase 2 NYX-783 study »

Aptinyx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.11

-0.11 (-2.11%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Conference/Events
PLx Pharma to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBRV

Nabriva Therapeutics

$2.08

0.045 (2.22%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
Nabriva Therapeutics announces FDA acceptance of lefamulin NDAs »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

WORX

SCWorx

$5.74

-0.07 (-1.20%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
SCWorx announces new customer service agreement »

SCWorx has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$17.56

0.07 (0.40%)

, JPM

JPMorgan

$105.56

3.14 (3.07%)

07:25
02/19/19
02/19
07:25
02/19/19
07:25
Hot Stocks
Arconic announces $700M accelerated share repurchase agreement »

Arconic (ARNC) announced…

ARNC

Arconic

$17.56

0.07 (0.40%)

JPM

JPMorgan

$105.56

3.14 (3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Hot Stocks
Intercept intends to file for OCA regulatory approval in U.S., Europe in 2H19 »

"We are thrilled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CNMD

Conmed

$71.94

0.73 (1.03%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Upgrade
Conmed rating change  »

Conmed reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 18

    May

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

, TLRY

Tilray

$76.46

-0.2 (-0.26%)

07:23
02/19/19
02/19
07:23
02/19/19
07:23
Recommendations
Aurora Cannabis, Tilray, CV Sciences, Cronos Group, General Cannabis, CannTrust Holdings, Aphria, MediPharm Labs, Canopy Growth, India Globalization Capital analyst commentary  »

Moody's price target…

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

TLRY

Tilray

$76.46

-0.2 (-0.26%)

CVSI

CV Sciences

$0.00

(0.00%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

CANN

General Cannabis

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

APHA

Aphria

$9.58

0.49 (5.39%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

IGC

India Globalization Capital

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept jumps 36% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Intercept announces results from Phase 3 REGENERATE study »

Intercept announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Earnings
Noble Midstream reports Q4 EPS $1.00, consensus $1.03 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

, UPS

UPS

$110.89

-0.91 (-0.81%)

07:20
02/19/19
02/19
07:20
02/19/19
07:20
Downgrade
XPO Logistics, UPS, FedEx, C.H. Robinson, Amazon.com rating change  »

Morgan Stanley downgrades…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

UPS

UPS

$110.89

-0.91 (-0.81%)

FDX

FedEx

$179.20

-4.74 (-2.58%)

CHRW

C.H. Robinson

$91.43

0.74 (0.82%)

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:19
02/19/19
02/19
07:19
02/19/19
07:19
Hot Stocks
Cooper Tire sees modest unit volume growth compared to 2018 »

Sees improving operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:18
02/19/19
02/19
07:18
02/19/19
07:18
Hot Stocks
Cooper Tire sees Q1 operating profit margin lower than Q1 »

Management expects Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Recommendations
XPO Logistics analyst commentary  »

Deutsche puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPTN

Optinose

$7.40

0.23 (3.21%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Hot Stocks
Optinose announces four additional Xhance patents from USPTO »

Optinose announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$62.77

0.19 (0.30%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Downgrade
Sensient rating change  »

Sensient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

CRSP

Crispr Therapeutics

$31.62

0.65 (2.10%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Hot Stocks
Crispr Therapeutics, StrideBio announce expanded strategic collaboration »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

Ceva

$28.91

1.23 (4.44%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Ceva announces collaboration to add C-V2X Rel. 14/15 support to the CEVA-XC DSP »

CEVA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.62

-0.045 (-2.70%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Plug Power begins production of next gen class 1 material handling equipment »

Plug Power announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Earnings
Cooper Tire reports Q4 EPS ex-items 66c, consensus 58c »

Reports Q4 revenue $770M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

ARAV

Aravive

$4.95

0.2 (4.21%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Aravive receives additional $2.6M disbursement from CPRIT for AVB-S6-500 »

Aravive announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.